DARPA awards Moderna $25m to develop mRNA therapies
This article was originally published in Scrip
Executive Summary
Moderna Therapeutics snagged a $25m award from the Defense Advanced Research Projects Agency (DARPA) to develop the firm's experimental messenger RNA (mRNA) therapeutics platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.